Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Zound delivers another record-breaking quarter

Zound fuels momentum by delivering another record-breaking quarter to round off a very successful first half of 2022, despite the challenging economic climate. Net sales for the second quarter of 2022 amounted to MSEK 723.4, an increase of 90 percent compared to the same period last year. In the first six months of 2022 Zound delivered revenue growth of 101 percent, with total sales reaching MSEK 1 279.1, while showing record profitability.After a series of successful product launches, an increasing demand on all key markets and an improving supply situation, Zound has managed to deliver

Qlife to participate in investor presentations in September 2022

Qlife will participate in two investor days in September where the company's CEO Thomas Warthoe presents the company and gives his comments on recent events and upcoming activities.September 26 at Stora Aktiedagen in LundVenue: Elite Hotel Ideon Time: 08.30-09.00 The presentation will be held in English and the event is open to the public, as well as live-streamed and availalble on demand at https://www.youtube.com/Aktiespararna September 27 at Redeye Theme Diagnostics (digital)Venue: RedeyeTime: 09.10-09.30 The presentations will be held in English and is available live-

RevolutionRace launches a new collection for kids & teens

RevolutionRace is proud to launch its first collection for kids and teens. The collection will be launched on September 20 and will initially consist of the brand's most popular trousers and fleeces in sizes 146-164."One of RevolutionRace's most important success factors is our direct communication with our customers. For a long time, we have experienced a great demand for products in smaller sizes adapted for kids and teens, so expanding towards a younger target group is therefore a natural next step. Being able to make our clothes available to the younger generation is part of making

EdmoLift 4.0 – the most significant investment in the company’s history

EdmoLift future-proofs the production with the greatest investment program ever. A 70 million SEK investment that ensures competitiveness for the next 10–15 years through a new production facility with more automated machinery and an investment in Härnösand, Sweden, location of the headquarter. Almost half of the time has passed for the expansion, where the premises of 1435 m² are to be in place at the beginning of next year. During the first half of 2023, a new machine park will also move into the building in the form of an automatic storage solution that will support a fiber

Concordium blockchain unveils novel solution to combat greenwashing with the world’s most data-driven carbon offsets

September 20, 2022, Zug, Switzerland - Concordium is proud to raise the bar for carbon credits and announce a partnership with Carbotanix  (CTX), one of the most data-driven carbon offsets on the market.   In an effort to restore trust in the offset process by making it data driven and transparent, Carbotanix’s carbon offset token is going to be built entirely on the Concordium blockchain, the world’s first, science-backed blockchain with an ID-layer at the protocol level designed with sustainability and governance in mind.   Developed through remote

BioStock Investor Meeting: Elicera Therapeutics presents

Gothenburg-based Elicera Therapeutics, headed by CEO Jamal El-Mosleh, travelled to Stockholm to present the company at the BioStock Investor Meeting. Elicera Therapeutics is a cell and gene therapy company with a fully developed technology platform called iTANK (ImmunoTherapies Activated with NAP for efficient Killing) to be used to fight cancer.See the presentation at biostock.se: https://www.biostock.se/en/2022/09/biostock-investor-meeting-elicera-therapeutics-presents/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Idogen’s cell therapy for hemophilia is presented in the prominent scientific journal Haemophilia

Idogen AB (publ) announced today that the highly-ranked scientific journal Haemophilia has published the company’s “Letter to the Editor” describing ItolDC-028, the IDO 8 program’s autologous cell therapy, and its potential to revolutionize the treatment of hemophiliac patients.   Haemophilia is one of the highest-ranking global scientific journals in the field of hemophilia that has accepted the documentation submitted by Idogen’s Chief Medical Officer and the company’s medical and scientific advisers for publication. This important milestone is one that the company has spent a long

Breakthrough results from new medical cannabis oil study

STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENO STENOCARE A/S (“Stenocare”) today announces groundbreaking results from their study of a new medical cannabis oil formulation. The study shows that the new formulation dramatically enhances the bioavailability and thus uptake of cannabinoids, regardless of meal consumption and inter-individual biological differences. The findings may have the potential to formulate novel medical cannabis products with vastly improved characteristics in the treatment of chronical pain and a variety of indications and diseases.THE

VENTSPILS SC – a new science and innovation center in Latvia

Research and explore goes hand in hand and are both tools used in innovation and education. Ventspils SC is an innovation center combining interactive galleries with education. Today, the interactive technology is as obvious in the teaching plan as physical books. The building is filled with knowledge and the vision is to attract not only locals, but people from the entire world. Construction started 2019 and the doors will open in summer 2022. Simultaneously as the construction of the building, is also the creation of the content inside the building. There’ll be seven interactive

Bidbrain launches effective campaign tool

Speqta AB's (“Speqta”) SaaS service Bidbrain is now launching a new campaign tool. The new functionality enables e-retailers to easily set different budgets and ROAS targets on different parts of their assortment. A requested feature that will help e-retailers to get more sales at the same ad spend and therefore be more profitable. Bidbrain is a SaaS platform for e-retailers who want to optimize their sales at a given ROAS (Return On Ad Spend). In addition to the optimization, the service is also providing more transparency and better control of the advertising. Now Bidbrain

SkartaNYAB Oyj - Managers' Transactions

SkartaNYAB PlcMANAGERS' TRANSACTIONS20 September 2022 at 09:30SkartaNYAB Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Andament Group OyPosition: Closely associated person (X) Legal person  (1):Person Discharging Managerial Responsibilities In IssuerName: Jukka JuolaPosition: Member of the Board (2):Person Discharging Managerial Responsibilities In IssuerName: Markku KankaalaPosition: Member of the Board Issuer: SkartaNYAB OyjLEI: 743700UX7WTIOT3QO547Notification type: INITIAL

Ratos Nomination Committee and 2023 AGM

Ratos's Annual General Meeting (AGM) will be held on 28 March 2023 at Lilla Cirkus, Cirkus, in Stockholm, Sweden.In accordance with the policy for appointing Ratos’s Nomination Committee, it is hereby announced that the company’s major owners/owner constellations have appointed a Nomination Committee with the Chairman of the Board Per-Olof Söderberg as the convener.The Nomination Committee comprises the following individuals:   · Jenny Parnesten, nominated by the Ragnar Söderberg Foundation, and own and related parties' holdings · Jan Söderberg, own holdings · Maria

BioStock Investor Meeting: Cyxone presents

Carl-Magnus Högerkorp recently assumed the role as acting CEO of Cyxone.  The biopharmaceutical company is currently awaiting approval of the phase II study with the candidate Rabeximod in rheumatoid arthritis. At the BioStock Investor Meeting in Stockholm, Högerkorp talked about the preparations for the start of the study and what lies ahead for the company.See the presentation at biostock.se: https://www.biostock.se/en/2022/09/biostock-investor-meeting-cyxone-presents/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Digia and Avalon join forces

Digia continues purposefully implementing its strategy and acquires Avalon, a company focused on digital marketing and customer experience development. Avalon’s understanding of the development of a data-based real-time customer experience and the management of that development, combined with Digia’s well-known business and design consulting expertise, strengthen Digia’s role in the market as a pioneering supplier of broader data- and analytics-based digital service packages. Together, the two companies are able to offer customers significant added value when it comes to digital services and

Nordea cancels repurchased shares

Nordea Bank AbpStock exchange release – Total number of voting rights and capital20 September 2022 at 9.15 EET Nordea has today cancelled 21,299,414 treasury shares in line with the decision by the Board of Directors. The shares were held for capital optimisation purposes and acquired through share buy-backs. The cancellation brings the total number of shares in Nordea to 3,714,243,282. The total number of votes attached to the shares is 3,714,243,282. The cancellation of the shares was registered with the Finnish Trade Register on 20 September 2022. The company holds 4,193,

Evusheld approved in EU for COVID-19 treatment

20 September 2022 07:00 GMT Evusheld long-acting antibody combination approved in the EU for the treatment of COVID-19 Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase III treatment trial   AstraZeneca's Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination, has been approved in the European Union (EU) for the treatment of adults and adolescents (aged 12 years and older weighing at least 40 kg) with COVID‑19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID‑19.

TIE Kinetix Signs Contract with Clopay Building Products for a 100% Cloud-Based Supply Chain

TIE Kinetix  announced today a new 5-year, $500,000 contract with Clopay Building Products, a leading manufacturer of residential and commercial garage doors. With this upgrade towards TIE Kinetix's FLOW Partner Automation platform, Clopay’s supply chain solution will move 100% to the cloud.The contract enables Clopay to move 100% to the cloud with a managed service agreement with TIE Kinetix, further optimizing their document exchange processes. All business partners of Clopay will continue to be able to exchange documents such as purchase orders, order

Peab builds tenant-owner apartments in Malmö

Peab has been commissioned to build 78 apartments in Limhamn in Malmö. The customer is HSB Projekt i Malmö HB and the contract is worth SEK 194 million.The project consists of four separate buildings with four to seven floors where the top floor is recessed in all the buildings. They are connected by a shared garage and basement with a tech room and storage.  “We’re proud to contribute with our expertise and by building more housing for Malmö residents. This is a good example of our locally produced community building,” says Peter Lindstedt, Region Manager Peab. The project is a

Inhalation Sciences to present findings of PreciseInhale clinical study at DDL 2022

(Stockholm 20 September 2022) ISAB’s conference paper on its study validating PreciseInhale[®] for clinical use has been accepted by the Drug Delivery to the Lungs (DDL) conference 2022 - one of the inhalation markets’ most influential events. The study demonstrates that PreciseInhale[®] outperformed standard commercial inhalers and improved ‘regional targeting’ of aerosols to specific areas of the lungs. The data will be presented as a Poster at the event.DDL 2022 (7- 9 December, Edinburgh, Scotland) will be a particularly important event as it will be the first to be held entirely onsite

Top-Line Data on Bexmarilimab Dose Variation

Faron Pharmaceuticals Ltd (“Faron or Company”)   Faron Pharmaceuticals Announces Top-Line Data on Bexmarilimab Dose Variation from MATINS Advanced Solid Tumor Patients   · Bexmarilimab was well tolerated in patients receiving higher dose levels or frequency of administration · Treatment induced significant systemic interferon (IFN) gamma increase - again showing the capacity of bexmarilimab to activate immune response in cancer patients, especially in patients with immunologically “cold” tumors · Higher baseline Clever-1 levels in the tumors was associated with

Ericsson publishes restated segment financials

· Ericsson has published restated segment financials for 2020 full year, 2021 by quarter and 2022 Q1 and Q2 following the changed reporting structure as of Q3 2022 · Conference call with CFO Carl Mellander for financial analysts, investors and journalists at 3:00 PM CEST, September 20, 2022As announced in May 2022, Ericsson (NASDAQ: ERIC) will start to report financials according to its new segment structure as of the third quarter 2022. To facilitate year-on-year comparisons, Ericsson today publishes the restated segment financials for 2020 full year; 2021 by quarter and 2022 Q1 and Q2.

Zalaris to deliver outsourced payroll services based on PeopleHub to global pharmaceutical company

Zalaris, the provider of payroll and HR solutions that simplify work life and support creating sustainable businesses, today announced the signing of an agreement with a leading global pharmaceutical company for the provision of outsourced payroll services in Germany and Switzerland.Zalaris has signed a five-year agreement to deliver a new outsourced payroll solution and outsourcing services to serve the global pharma company’s 6,000+ employees in Germany and Switzerland. The solution that will be implemented over the next 18 months with first go-live in July 2023 is based on Zalaris

Composition of Nordea Bank Abp’s Shareholders’ Nomination Board

Nordea Bank AbpStock exchange release – Other information disclosed according to the rules of the Exchange20 September 2022 at 9.00 EET Nordea’s Shareholders’ Nomination Board has been appointed. The Nomination Board consists of the Chair of the Board of Directors and the four largest shareholders, who on 31 August represent the largest number of voting rights and wish to participate in the work of the Nomination Board. The members of the Nomination Board are: · Niko Pakalén, Partner, Cevian Capital · Lars Ingemann Nielsen, Executive Vice President and CFO, Nordea-fonden

There are no items matching the current filter
There are no more items matching the current filter
Back to top